Methods and kits for diagnosing osteoarthritis and predicting progression
AssigneeNew York University
InventorsMukundan Attur, Steven B. Abramson
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.
Claims23
A method for treating osteoarthritis in a subject, wherein the subject has been diagnosed with osteoarthritis but does not have severe osteoarthritis, said method comprising the steps of:
- (a) measuring in a blood plasma sample obtained from the subject the plasma level of one or more protein(s) selected from the group consisting of total matrix metalloproteinase 9 (tMMP-9), proMMP-9 (pMMP-9), and interleukin-1 receptor antagonist (IL1-Ra);
- and
- (b) administering an osteoarthritis treatment to the subject whose plasma level of one or more protein(s) selected from the group consisting of tMMP-9, pMMP-9, and IL1-Ra is increased by at least 2 fold as compared to a control plasma level(s) of said protein(s).
A method for treating osteoarthritis in a subject, the method comprising administering an osteoarthritis treatment to a subject with elevated plasma level of one or more protein(s) selected from the group consisting of total matrix metalloproteinase 9 (tMMP-9), proMMP-9 (pMMP-9), and interleukin-1 receptor antagonist (IL1-Ra), wherein the subject does not have severe osteoarthritis.
A method for determining whether a subject diagnosed with osteoarthritis is at increased risk for progression to severe osteoarthritis within 12-24 months, said method comprising the steps of:
- (a) preparing a blood plasma sample obtained from the subject in the presence of heparin;
- (b) measuring in the blood plasma sample prepared in step (a) a plasma level of one or more protein(s) selected from the group consisting of total matrix metalloproteinase 9 (tMMP-9), proMMP-9 (pMMP-9), and interleukin-1 receptor antagonist (IL1-Ra);
- (c) comparing the plasma level(s) measured in step (b) to a control plasma level(s) of said protein(s), and (d) identifying the subject as being at increased risk for progression to severe osteoarthritis within 12-24 months when the plasma level of one or more protein(s) selected from the group consisting of tMMP-9, pMMP-9, and IL1-Ra in step (b) is increased by at least 2 fold as compared to the control plasma level(s) of said protein(s).
Dependencies are inferred from the claim text.